

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **OrbusNeich Medical Group Holdings Limited**

**業聚醫療集團控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6929)**

### **INSIDE INFORMATION ANNOUNCEMENT**

This announcement is made by OrbusNeich Medical Group Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The board of directors of the Company is pleased to announce that on 22 November 2023 (Germany time), the Group reached a major milestone in relation to its acquisition of 100% ownership in Eucatech AG (“**Target Company**”) which was going through insolvency proceedings (the “**Acquisition**”). On 22 November 2023 (Germany time), the creditors of the Target Company voted and passed the plan (the “**Plan**”) submitted by the Group to continue the business operations of the Target Company. Pursuant to the Plan, the total consideration of the Acquisition is EUR2,400,000. The Plan is expected to take legal effect on or around 7 December 2023 (Germany time), after which the Target Company will become solvent and a wholly owned subsidiary of the Group.

As all relevant applicable percentage ratios calculated in accordance with the Listing Rules of the Acquisition are less than 5%, the Acquisition does not constitute a notifiable transaction of the Company under Chapter 14 of the Listing Rules.

## **The Target Company**

The Target Company is principally engaged in the development, manufacture and distribution of minimally invasive cardiovascular and endovascular products. The complementary nature of Target company product portfolio which includes a CE mark approved coronary drug eluting stent, a coronary drug eluting balloon, and peripheral self-expanding stent and coated balloon, broadens our offerings. The incorporation of these products, not only brings about technological synergies but also allow us to stay ahead of market trends, reinforces our market presence and distribution network.

Ultimately, the Group's focus remains on meeting clinicians needs and enhancing quality of life for patients.

**Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**OrbusNeich Medical Group Holdings Limited**  
**Mr. David CHIEN**

*Chairman, Executive Director and Chief Executive Officer*

Hong Kong, 23 November 2023

*As at the date of this announcement, the Board of the Company comprises Mr. David CHIEN, Ms. Kwai Ching Denise LAU and Mr. Wing Shing CHEN as Executive Directors; Mr. Ching Chung John CHOW, Mr. Ting San Peter Lionel LEUNG and Dr. Yi ZHOU as Non-Executive Directors; and Mr. Yip Keung CHAN, Mr. Ka Keung LAU BBS, MH, JP and Dr. Lai Fan Gloria TAM as Independent Non-executive Directors.*